[The preliminary results of a phase II randomized clinical trial of high-dose toremifene chemosensitization in stage IIIB/IV non-small cell lung cancer]

Hua Cheng; Yilong Wu; Lijia Gu; Weineng Feng; Yimin Weng; Chao Cheng; Wenzhao Zhong; Shaohong Huang

doi:10.3779/j.issn.1009-3419.2003.05.03

[The preliminary results of a phase II randomized clinical trial of high-dose toremifene chemosensitization in stage IIIB/IV non-small cell lung cancer]

Zhongguo Fei Ai Za Zhi. 2003 Oct 20;6(5):335-8. doi: 10.3779/j.issn.1009-3419.2003.05.03.

[Article in Chinese]

Authors

Hua Cheng¹, Yilong Wu, Lijia Gu, Weineng Feng, Yimin Weng, Chao Cheng, Wenzhao Zhong, Shaohong Huang

Affiliation

¹ Department of Thoracocardiac Disease, The 5th University Hospital, Sun Yat sen University, Zhuhai, Guangdong 519000, P.R.China.

PMID: 21306673
DOI: 10.3779/j.issn.1009-3419.2003.05.03

Abstract

Background: To investigate whether high-dose toremifene can enhance the efficacy of chemotherapy in non small cell lung cancer.

Methods: Untreated stage IIIB/IV non-small cell lung cancer patients were randomly devided into group A (high-dose toremifene combined with the platinum-based chemotherapy) or group B (the same platinum-based chemotherapy alone).

Results: A total of 30 eligible patients had been recruited. Hemotologic and nonhemotologic toxicities were similar with no statistic difference. The median survival for group A was 8 months, 95% CI (6.63-9.37) versus 7.5 months, 95% CI (4.75-10.25) for group B ( P =0.9). One year-survival rate was 31% for group A versus 28% for group B ( P =0.87). The response rate was 25% for group A versus 21% for group B ( P =0.99).

Conclusions: The results suggest that high-dose toremifene does not enhance the efficacy of platinum-based chemotherapy for IIIB/IV non-small cell lung cancer but toxicities are well tolerated.

Publication types

English Abstract